1. India Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Krsnaa Diagnostics Limited

Krsnaa Diagnostics Limited

515.65
INR
+0.65
(+0.13%)
29.66EPS
18.08P/E
17.64BMarket Cap
Nov 14Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
66.64
82.31
126.27
152.44
155.15
195.18
222.1
238.49
251.57
Basic EPS, GAAP
-18.49
-35.66
58.9
22.89
19.78
17.9
24.03
31.3
30.07
Free Cash Flow per Basic Share
-13.22
-12.4
11.38
-1.27
-20.72
-53.41
-12.17
-23.5
- -
Dividend per Share
- -
- -
- -
- -
2.5
2.72
2.5
2.75
- -
Book Value per Share
-31.83
-67.52
-3.35
217.98
235.28
250.79
273.39
302.23
- -
Tangible Book Value per Share
-32.1
-68
-3.74
217.24
234.38
250.04
272.48
300.74
- -
Basic Weighted Avg Shares
31
31
31
30
31
32
32
32
32
Sales/Revenue/Turnover
2,092
2,584
3,965
4,555
4,871
6,196
7,172
7,728
8,153
Operating Margin (%)
15.43
11.77
14.35
19.83
14.21
11.26
14.2
15.72
14.92
Depreciation Expense
256
323
374
414
538
745
883
905
968
Net Income, GAAP
-581
-1,120
1,849
684
621
568
776
1,014
975
Effective Tax Rate (%)
- -
- -
37.41
20.95
22.56
18.81
24.42
22.2
22.27
Profit Margin (%)
-27.75
-43.32
46.65
15.02
12.75
9.17
10.82
13.13
11.95
Working Capital
153
328
643
2,131
1,237
1,397
1,091
4,631
- -
LT Debt
921
1,227
1,680
331
243
419
472
4,683
- -
Total Equity
-849
-1,970
2,319
6,844
7,387
8,098
8,828
9,804
- -
Return on Invested Capital (%)
- -
- -
14.47
12.06
7.22
6.54
7.86
7.28
- -
Return on Capital (%)
- -
- -
80.55
13.75
8.97
7.84
9.15
9.74
- -
Return on Common Equity (%)
- -
- -
- -
- -
8.73
7.34
9.17
10.89
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
660
- -
LT Borrowings
- -
4,371
- -
LT Finance Leases
- -
311
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
23,399
16,878
17,640

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
7,383
- -
Cash, Cash Equivalents & STI
- -
3,607
- -
Accounts Receivable, Net
- -
2,955
- -
Inventories
- -
267
- -
Total Current Liabilities
- -
2,752
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
660
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.56%
11.06%
Free Cash Flow
- -
336.26%
93.79%
Net Income, GAAP
- -
-2.69%
30.7%
Sales/Revenue/Turnover
- -
14.5%
7.75%
Total Cash Common Dividend
- -
- -
10.52%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,702
1,863
1,745
1,861
7,172
2026
1,930
2,060
1,812
1,926
7,728
2027
2,355
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.55
6.07
6.01
6.4
24.03
2026
6.35
7.38
4.72
12.86
31.3
2027
5.1
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
2.75
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mitesh Dave
Full Time Employees
6,040
Sector
Health services
Industry
Medical/Nursing services
Address
S.No.243,A-Hissa No.6/6 Pune MH India 411019
IPO Date
Aug 16, 2021
Website
krsnaadiagnostics.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Krsnaa Diagnostics Limited operates as one of India's largest providers of technology-enabled diagnostic services, specializing in radiology, pathology, and teleradiology through public-private partnerships with government hospitals, medical colleges, and community health centers across semi-urban and rural areas. The company offers comprehensive radiology services via 148 centers equipped with CT scans, MRI machines, ultrasound, mammography, DEXA, and digital X-ray; teleradiology through India's first NABH-accredited hub with 1,443 tele-reporting centers; and pathology services encompassing 120 processing labs, 1,895 collection centers, and over 2,544 pathological tests including routine biochemistry, specialized molecular diagnostics, histopathology, flow cytometry, and genetics via NGS, supported by home collection, health packages for diabetes, cardiac, thyroid, and wellness screening, and advanced automation. Founded in 2010 and headquartered in Pune, Maharashtra, Krsnaa serves patients across 17 states and union territories spanning 150+ districts, with a network exceeding 3,600 centers and operations in both B2B (PPP contracts averaging 5-10+ years for pathology and 10+ years for radiology) and B2C segments including company-owned labs in major cities and franchise models. Recent developments include a 23.53% stake acquisition in Apulki Healthcare in 2024 to become the exclusive diagnostics partner for its cancer and cardiac hospitals over 30+ years; a strategic alliance with Medikabazaar and United Imaging investing over ₹300 crore to deploy 30+ advanced imaging centers in Tier-2/3 cities; expansion of 40 retail labs, 20 city scan centers, and 375 pathology collection centers in Q1 FY25 alongside new PPP projects in Maharashtra (17 MRI/CT), Rajasthan, Odisha, Assam, and Madhya Pradesh; and record H1 FY26 revenue growth of 12% with 19% net profit increase, driven by Rajasthan rollout and patient volume surges.